Wellington Management Group LLP Sells 1,354,898 Shares of Neurocrine Biosciences, Inc. $NBIX

Posted by Geri Gentry on Sep 10th, 2026

Wellington Management Group LLP trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 97.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,641 shares of the company’s stock after selling 1,354,898 shares during the quarter. Wellington Management Group LLP’s holdings in Neurocrine Biosciences were worth $5,838,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of NBIX. BlackRock Inc. bought a new stake in Neurocrine Biosciences in the second quarter worth about $2,310,886,000. AQR Capital Management LLC grew its position in shares of Neurocrine Biosciences by 18.0% during the 4th quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock valued at $462,652,000 after acquiring an additional 498,058 shares during the period. Renaissance Technologies LLC increased its stake in shares of Neurocrine Biosciences by 8.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after purchasing an additional 180,100 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock worth $291,342,000 after purchasing an additional 34,457 shares during the last quarter. Finally, Los Angeles Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 7.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock worth $178,248,000 after purchasing an additional 88,522 shares during the period. 92.59% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 4,367 shares of the stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $181.02, for a total transaction of $790,514.34. Following the transaction, the insider directly owned 16,225 shares in the company, valued at approximately $2,937,049.50. This represents a 21.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie Norwalk sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total value of $227,512.50. Following the transaction, the director directly owned 1,588 shares in the company, valued at approximately $289,031.88. This represents a 44.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 40,188 shares of company stock worth $7,118,633 over the last three months. 4.60% of the stock is owned by insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX opened at $155.14 on Thursday. Neurocrine Biosciences, Inc. has a fifty-two week low of $122.14 and a fifty-two week high of $186.12. The stock has a market cap of $15.77 billion, a PE ratio of 22.75, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38. The stock has a fifty day moving average of $165.18 and a 200-day moving average of $151.02.

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping analysts’ consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business had revenue of $959.00 million for the quarter, compared to analyst estimates of $891.16 million. During the same quarter in the prior year, the firm posted $1.65 EPS. Neurocrine Biosciences’s revenue was up 39.5% on a year-over-year basis. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 7.25 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Piper Sandler raised their target price on Neurocrine Biosciences from $207.00 to $210.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $200.00 to $210.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Stifel Nicolaus lifted their price objective on Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Wedbush boosted their price objective on Neurocrine Biosciences from $185.00 to $194.00 and gave the company an “outperform” rating in a research note on Monday, August 3rd. Finally, Truist Financial upped their price objective on shares of Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Neurocrine Biosciences currently has an average rating of “Moderate Buy” and an average price target of $201.05.

Check Out Our Latest Stock Analysis on NBIX

Neurocrine Biosciences Company Profile

(Free Report)

Neurocrine Biosciences, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company develops therapies for conditions with significant unmet medical needs, using expertise in neuroscience and endocrine biology.

Its primary commercial product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.